The phosphatidylinositol 3-kinase (PI3K)/Akt pathway plays a crucial role in various cellular processes and is aberrantly activated in cancers, contributing to the occurrence and progression of tumors. In this review, we discuss the roles of the PI3K/Akt pathway in various cancer phenotypes, review the current statuses of different PI3K/Akt inhibitors, and introduce combination therapies consisting of signaling inhibitors and conventional cancer therapies.
Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.
Read the full paper
Access the original peer-reviewed research via OpenAlex.
| Category | 🧬 Medicine & Biology |
| Published | Dec 16, 2021 |
| Journal | Signal Transduction and Targeted Therapy |
| Authors | Yan He, Miao Sun, Guo Geng Zhang, Jing Yang, Kui Sheng Chen |
| DOI | 10.1038/s41392-021-00828-5 |
| Citations | 1,770 |
| Source | OpenAlex |